Treatment advance sits at the center of this dementia and brain health question.
Yes, Alzheimer’s treatments have advanced through European regulatory approval, marking a watershed moment for brain health. The European Commission granted marketing authorization to lecanemab (LEQEMBI®) on April 15, 2025, making it the first disease-modifying treatment for Alzheimer’s disease approved anywhere in the EU27 and EEA Member States. Months later, in September 2025, a second anti-amyloid therapy, donanemab (Kisunla®), also received approval after an initial setback, offering European patients two distinct options for slowing cognitive decline in early-stage disease. This article examines what these regulatory approvals mean, how they work, who can access them, and what barriers remain to widespread use across Europe.
Table of Contents
- What Does European Approval Mean for Early Alzheimer’s Disease?
- How Lecanemab Works and What the Safety Data Shows
- Donanemab’s Path to Approval and How It Differs
- Which Patients Can Access These Treatments and How?
- The Reality of Infusion-Related Reactions and Monitoring Requirements
- Current Availability and the Rollout Across EU Member States
- What These Approvals Mean for Alzheimer’s Research and Future Treatments
- Conclusion
- Frequently Asked Questions
What Does European Approval Mean for Early Alzheimer’s Disease?
european regulatory approval represents formal recognition that these treatments slow the progression of early cognitive decline with clinical evidence supporting their use. Lecanemab demonstrated a 31% reduction in clinical decline on the Clinical Dementia Rating Scale at 18 months compared to placebo—a meaningful but modest effect size that reflects the complexity of Alzheimer’s disease. For comparison, this marks the first time a disease-modifying approach has cleared the rigorous European Commission review, whereas previous treatments only managed symptoms like memory loss or behavioral changes without addressing underlying neurodegeneration.
The regulatory pathway itself proved challenging. Donanemab initially received a negative opinion from the European Medicines Agency in March 2025, yet the European Commission overturned this decision and granted approval in September 2025 after the manufacturer submitted additional data and a modified dosing regimen. This reversal illustrates both the scientific complexity and the regulatory tension between approving promising treatments quickly versus waiting for perfect safety data—a debate that characterizes modern neurodegenerative medicine.
How Lecanemab Works and What the Safety Data Shows
Lecanemab is an intravenous infusion administered once every two weeks that targets amyloid-beta, the protein that accumulates in Alzheimer’s brains and is believed to drive neurodegeneration. The drug binds to amyloid plaques and facilitates their clearance, attacking the disease at what many researchers consider its biological root. However, this mechanism carries real risks: amyloid-related imaging abnormalities (ARIA) are brain changes visible on MRI that can indicate either microhemorrhages (ARIA-H, affecting more than 1 in 10 people) or brain swelling (ARIA-E, occurring in up to 1 in 10 people).
The safety trade-off is significant and not always discussed plainly. Some patients receiving lecanemab experience infusion-related reactions, and the amyloid-related imaging abnormalities require careful neurological monitoring and patient selection. Carriers of the ApoE ε4 gene, which increases Alzheimer’s risk, face higher rates of these complications, which is why lecanemab’s approval is limited to non-carriers or heterozygotes with confirmed amyloid pathology. Patients must be screened for genetic risk and undergo baseline MRI before starting treatment, and continued monitoring is essential.
Donanemab’s Path to Approval and How It Differs
Donanemab’s regulatory journey proved more contentious than lecanemab’s, beginning with a negative EMA opinion in March 2025 before the European Commission approved it months later. The drug similarly targets amyloid but uses a modified titration dosing regimen designed to maintain efficacy while reducing the rate of amyloid-related imaging abnormalities. Clinical evidence came from the TRAILBLAZER-ALZ 2 and 6 trials, which tested this revised approach in patients with mild cognitive impairment and mild dementia who carry one or no copies of the ApoE4 gene.
The initial rejection followed by reversal reveals a crucial nuance: regulatory bodies sometimes disagree, and manufacturers can appeal or resubmit with additional information. Donanemab’s approval demonstrates that a second anti-amyloid monoclonal antibody could reach European patients despite initial skepticism, though it also highlights the scientific uncertainty around these treatments. Unlike some countries where insurance coverage is automatic, European patients may face variable access depending on their country’s health system and willingness to fund these expensive therapies.
Which Patients Can Access These Treatments and How?
Both lecanemab and donanemab are approved only for early symptomatic Alzheimer’s disease—meaning mild cognitive impairment or mild dementia with confirmed amyloid pathology. A patient with advanced dementia affecting daily functioning would not qualify, nor would a person with cognitive concerns but no biological evidence of amyloid accumulation. This restriction reflects the evidence: both drugs were tested in early-stage populations, and giving them to people with advanced disease risks harm without benefit.
Lecanemab operates through a controlled access program, with Austria and Germany becoming the first EU markets to launch in 2025, followed by other member states at varying paces. Access is not uniform across Europe; some countries approved funding quickly while others deliberate on cost-effectiveness, and availability depends on referral pathways to specialized memory clinics. Patients must undergo amyloid positron emission tomography (PET) imaging or cerebrospinal fluid testing to confirm disease pathology—a requirement that creates bottlenecks in countries with limited neuroimaging capacity.
The Reality of Infusion-Related Reactions and Monitoring Requirements
The side effect profile demands candid discussion. Infusion-related reactions, which include fever, chills, and flu-like symptoms, occur frequently enough that pre-medication and slow infusion protocols are standard practice. More concerning, amyloid-related imaging abnormalities can be asymptomatic—a patient may harbor brain microhemorrhages visible only on MRI without experiencing symptoms, yet these findings may warrant stopping treatment. Managing these treatments in real-world practice requires infrastructure many European healthcare systems lack.
Patients need regular MRI scans to monitor for ARIA, regular blood work, and close neurological follow-up. In countries with overburdened neurology clinics, this becomes a practical barrier even where the drug is technically approved. Some patients will tolerate treatment well and experience no ARIA; others will develop imaging abnormalities and require treatment cessation. The pivotal trials suggest that stopping the drug halts further ARIA progression, but long-term outcomes from real-world use remain uncertain.
Current Availability and the Rollout Across EU Member States
As of late 2025, lecanemab has launched in Austria and Germany, with additional EU member states expected to follow as healthcare systems negotiate pricing and establish patient pathways. The drug costs tens of thousands of euros per patient annually, making reimbursement decisions the primary bottleneck in most countries. France, Italy, Spain, and other large European economies have not yet provided public funding, leaving patients and their families to navigate private or out-of-pocket options or to travel for treatment.
Donanemab’s rollout will follow a similar pattern—regulatory approval does not guarantee immediate patient access. Each country’s health authority must evaluate cost-effectiveness, negotiate pricing with the manufacturer, and establish referral processes. The time lag between European Commission approval and actual patient access can stretch to years in slower-moving systems. Patients in countries without public funding face a cruel reality: a disease-modifying treatment exists but remains financially inaccessible.
What These Approvals Mean for Alzheimer’s Research and Future Treatments
Lecanemab and donanemab’s approvals validate decades of research into amyloid as a therapeutic target and open the door for third and fourth-generation anti-amyloid drugs in European trials. Eli Lilly, Biogen, and smaller biotech firms are developing next-generation amyloid-targeting agents, some with improved safety profiles or oral dosing that could overcome the infusion requirement. The regulatory precedent established by these approvals accelerates the pathway for similar drugs.
Critically, these treatments address only amyloid pathology and do not reverse established cognitive decline—they slow it in early stages. Future approvals may target tau pathology, neuroinflammation, or other mechanisms that emerge as important. The field recognizes that combination therapy—potentially combining anti-amyloid and anti-tau approaches—may prove more effective than monotherapy, a direction likely to shape European clinical development over the next 5 to 10 years. For now, lecanemab and donanemab represent the first real disease-modifying foothold in Alzheimer’s treatment globally.
Conclusion
European regulatory approval of lecanemab and donanemab marks a genuine advance in Alzheimer’s treatment, offering patients with mild cognitive impairment or mild dementia a biological rationale for hope. These are not cures and carry real safety risks, but they demonstrate that slowing neurodegeneration is achievable in early disease when amyloid pathology is active. The 31% reduction in decline that lecanemab offers translates to months of preserved function—a meaningful difference for someone early in disease progression.
The true test now lies in real-world implementation across Europe’s fragmented healthcare systems. Regulatory approval does not guarantee patient access; funding decisions, specialist availability, and diagnostic capacity will determine whether these treatments help thousands or remain available only to wealthy patients in well-resourced countries. Clinicians, patients, and policymakers should monitor donanemab and lecanemab’s use over the coming years to confirm safety and effectiveness match the clinical trial evidence and to identify which patients benefit most.
Frequently Asked Questions
If I’ve already been diagnosed with moderate dementia, can I receive lecanemab or donanemab?
No. Both treatments are approved only for mild cognitive impairment or mild dementia with confirmed amyloid pathology. If cognitive decline is already advanced, these drugs have not been studied and may not help.
Do I need amyloid imaging (PET scan) before starting treatment?
Yes, both treatments require confirmation of amyloid pathology through either PET imaging or cerebrospinal fluid testing. You cannot start treatment based on symptoms alone.
How often do I need MRI scans once I start lecanemab?
Baseline MRI is required, and repeat imaging is scheduled throughout treatment to monitor for amyloid-related imaging abnormalities. The exact schedule depends on your memory clinic, but regular monitoring is essential.
Is donanemab safer than lecanemab because it was initially rejected?
Not necessarily. Donanemab’s initial negative opinion was later overturned by the European Commission, and the modified dosing regimen may reduce certain side effects, but both drugs carry similar risks of amyloid-related imaging abnormalities.
How much cognitive improvement can I expect?
Neither drug reverses cognitive decline; they slow it. Lecanemab showed a 31% reduction in decline compared to placebo over 18 months—roughly meaning slower progression, not recovery of lost function.
Will my country’s health system cover these drugs?
Coverage varies widely. Austria and Germany fund lecanemab as of 2025, but many other EU countries have not yet approved reimbursement. Check with your national health authority or neurologist.
You Might Also Like
- European regulators weigh approval of experimental early-stage Alzheimer’s drug candidate
- How new policy brings professional home support to families with newborns
- Who’s stepping up? Major shifts in Alzheimer’s care nonprofit leadership team
For more, see NIH MedlinePlus — dementia.
